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published sources. Societal utility scores were obtained from a
standard gamble study conducted in Canadians. Costs (2006
CDN dollars) and outcomes were discounted at 5%. Incremen-
tal cost-effectiveness ratios (ICERs) were estimated relative to
lumiracoxib. Sensitivity analyses were conducted for all input
parameters to identify inﬂuential inputs. RESULTS: Lumiracoxib
was more effective and less costly (i.e. dominated) in all sub-
groups when compared to celecoxib. Compared to celecoxib,
lumiracoxib was predicted to reduce clinical and complicated
events in non-ASA patients by 10 and 55% respectively. ICERs
ranged from −$11,253/QALY to −$187,203/QALY for average
risk patients and became more favorable over the cohort’s life-
time. Results were most sensitive to the utility of arthritis and
adverse event rates but the interpretation was robust. Compared
to the majority of secondary treatment algorithms, lumiracoxib
also had an attractive cost-effectiveness proﬁle. CONCLUSION:
From an economic perspective, lumiracoxib is an attractive treat-
ment choice for Canadian OA patients and is more cost-effec-
tive than celecoxib.
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OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, pro-
gressive inﬂammatory form of arthritis with annual estimated
costs of US $6720 per patient. Given the chronic nature of AS
and the high costs of the newer treatments such as tumor necro-
sis factor (TNF) inhibitors, the goal of this study is to conduct
an incremental cost-effectiveness analysis of TNF inhibitors com-
pared with a standard treatment option in patients with AS.
METHODS: A Markov simulation model (one-year) was used
to evaluate the incremental cost-effectiveness of three treatments
in patients with AS: 1) etanercept; 2) inﬂiximab; and 3) standard
treatment (NSAIDs). The decision model assumed a base-case
population of 40 year-old men and the efﬁcacy and withdrawal
data were based on clinical trials of respective drugs. The effec-
tiveness measure was Assessments in Ankylosing Spondylitis
20% Response data (ASAS 20) and the incremental cost-effec-
tiveness ratio (ICER) was calculated as additional cost per ASAS
20, compared with the next most expensive option. The study
was conducted from a payer’s perspective and the cost of treat-
ment with each agent included medication costs, monitoring
costs, infusion administration costs, and physician visit costs.
One-way sensitivity analyses were conducted to test the robust-
ness of study results. RESULTS: The annual costs for standard
treatment, etanercept, and inﬂiximab were $3000, $12,000 and
$13,000, respectively. The ICER of etanercept compared with
standard treatment was $10,860.96/ASAS 20, while the ICER 
of inﬂiximab compared with standard treatment was
$26,314.59/ASAS 20. One-way sensitivity analyses indicated
that the conclusions were relatively stable to variations in model
assumptions. CONCLUSION: The introduction of TNF
inhibitors has represented a signiﬁcant advance in the available
treatments for patients with AS. Thus, demonstrating the cost-
effectiveness of these new treatments can be a critical factor in
determining the acceptability of these new therapies especially
since these agents may offer improved function and signiﬁcant
downstream economic savings.
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OBJECTIVES: To compare the cost-effectiveness of once-daily
tramadol extended-release (ER) and branded and generic tra-
madol immediate-release (IR) formulations for the treatment of
chronic osteoarthritis pain from a managed care payer perspec-
tive. METHODS: A one-year model was constructed to compare
the cost per percent pain reduction using tramadol formulations
for treating chronic osteoarthritis pain. Prevalence, clinical efﬁ-
cacy, and model assumptions were based on product labels, clin-
ical study reports, and published literature. Overall costs
included: drug costs (Red Book), concomitant drug costs to treat
adverse events (AEs), and resource utilization costs (ofﬁce visits,
emergency room visits, and inpatient hospitalizations). Effec-
tiveness was deﬁned as percent pain reduction, calculated as
mean change from baseline in pain intensity score (ER 35.37%
and IR 29.63%). Based on the literature a 30% pain reduction
is considered clinically meaningful (Farrar 2001). In the cost-
effectiveness analysis, a linear relationship across all costs and
effectiveness ranges was assumed to extrapolate costs per clini-
cally meaningful pain reduced (30%). Univariate sensitivity
analyses were conducted to determine model inputs with the
most inﬂuence on model results. RESULTS: The overall annual
cost of therapy per patient was $8238 (ER), $8120 (branded IR),
and $7561 (generic IR). The annual patient cost for every per-
centage pain reduction was lowest for ER ($232.90) followed by
generic IR ($255.18) and branded IR ($274.04). The incremen-
tal cost-effectiveness ratio (ICER) for ER versus branded IR was
$20.48 and the ICER for ER versus generic IR was $118.00 per
percentage pain reduction. Sensitivity analyses indicated that the
drug cost for ER has the most inﬂuence on the cost-effectiveness
ratio. CONCLUSION: This analysis suggests the drug acquisi-
tion cost of ER may be offset by its clinical effectiveness, result-
ing to be a more cost-effective treatment alternative.
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OBJECTIVES: To evaluate the all-cause health care costs among
patients with PsA, who received anti-TNF treatment.
METHODS: A retrospective study using the PharMetrics data-
base, compiled from managed care plans throughout the United
States from January 2000 through June 2005, was conducted.
Patients continuously enrolled for 6 months pre- and 12 months
post-diagnosis, and having 2 distinct claims of PsA, were
included in the study. A 6-month period prior to the index diag-
nosis date was used to establish anti-TNF and/or MTX treat-
ment, naïve patients, and to identify new PsA patients. Per
patient per month treatment (PPPM) costs was calculated for
patients during their treatment period. The cost of adverse events
could not be identiﬁed separately in this analysis. A multivariate
model was used to adjust for covariates including age, gender,
number of medical visits, Charlson Co-morbidity Index, and pre-
period health care costs. RESULTS: A total of 357 patients with
PsA were included in the analysis. Nearly half of the patients
